Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1179
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Administration
- Subcutaneous
01
Overview
SHR-1179 is an investigational therapeutic biologic candidate developed by Guangdong Hengrui Pharmaceuticals (a subsidiary of Jiangsu Hengrui Pharmaceuticals) for weight management in adults with obesity. It is administered subcutaneously and is currently being evaluated in a Phase 1 randomized, double-blind, dose-escalation, placebo-controlled clinical trial to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. The specific biological target and mechanism of action of SHR-1179 have not been publicly disclosed.
- Other names
- SHR-1179 injectionSHR1179 injectionSHR 1179 injection
Beyond the preview
Go deeper on SHR-1179.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1179.